Surgical Treatment of Pancreatic Cancer
and operative mortality in the United States, N Engl J Med, 2003;349:2117–27.
58. van Heek NT, Kuhlmann KF, Scholten RJ, et al., Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands, Ann Surg, 2005;242:781–8, discussion 788–90.
59. Cady B, Basic principles in surgical oncology, Arch Surg, 1997;132:338–46.
60. Traverso LW, The Longmire I, II, and III operations, Am J Surg, 2003;185:399–406.
61. Lin PW, Lin YJ, Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy, Br J Surg, 1999;86:603–7.
62. Seiler CA, Wagner M, Schaller B, et al., Pylorus preserving or classical Whipple operation in tumors. Initial clinical results of a prospective randomized study, Swiss Surg, 2000;6:275– 82.
63. Seiler CA, Wagner M, Sadowski C, et al., Randomized prospective trial of pylorus-preserving vs. Classic duodenopancreatectomy (Whipple procedure): initial clinical results, J Gastrointest Surg, 2000;4:443–52.
64. Nguyen TC, Sohn TA, Cameron JL, et al., Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors, J Gastrointest Surg, 2003;7:1–9.
65. Tran KT, Smeenk HG, van Eijck CH, et al., Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors, Ann Surg, 2004;240:738–45.
66. Lin PW, Shan YS, Lin YJ, Hung CJ, Pancreaticoduodenectomy for pancreatic head cancer: PPPD versus Whipple procedure, Hepatogastroenterology, 2005;52:1601–4.
67. Seiler CA, Wagner M, Bachmann T, et al., Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results, Br J Surg, 2005;92:547–56.
68. Karanicolas PJ, Davies E, Kunz R, et al., The pylorus: take it or leave it? Systematic review and meta-analysis of pylorus- preserving versus standard whipple
pancreaticoduodenectomy for pancreatic or periampullary cancer, Ann Surg Oncol, 2007;14:1825–34.
69. Diener MK, Knaebel HP, Heukaufer C, et al., A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma, Ann Surg, 2007;245:187–200.
70. Srinarmwong C, Luechakiettisak P, Prasitvilai W, Standard Whipple’s operation versus pylorus preserving pancreaticoduodenectomy: a randomized controlled trial study, J Med Assoc Thai, 2008;91:693–8.
71. Diener MK, Heukaufer C, Schwarzer G, et al., Pancreaticoduodenectomy (classic Whipple) versus pylorus- preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma, Cochrane Database Syst Rev, 2008;(2):CD006053.
72. Iqbal N, Lovegrove RE, Tilney HS, et al., A comparison of pancreaticoduodenectomy with pylorus preserving pancreaticoduodenectomy: a meta-analysis of 2822 patients, Eur J Surg Oncol, 2008;34:1237–45.
73. Patel AG, Toyama MT, Kusske AM, et al., Pylorus-preserving Whipple resection for pancreatic cancer. Is it any better?, Arch Surg, 1995;130:838–42.
74. Yeo CJ, Cameron JL, Maher MM, et al., A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy, Ann Surg, 1995;222:580–88.
75. Bassi C, Falconi M, Molinari E, et al., Reconstruction by pancreaticojejunostomy versus pancreaticogastrostomy following pancreatectomy: results of a comparative study, Ann Surg, 2005;242:767–71.
76. Takano S, Ito Y, Watanabe Y, et al., Pancreaticojejunostomy versus pancreaticogastrostomy in reconstruction following pancreaticoduodenectomy, Br J Surg, 2000;87:423–7.
77. Duffas JP, Suc B, Msika S, et al.; French Associations for Research in Surgery, A controlled randomized multicenter trial of pancreatogastrostomy or pancreatojejunostomy after pancreatoduodenectomy, Am J Surg, 2005;189:720–9.
78. McKay A, Mackenzie S, Sutherland FR, et al., Meta-analysis of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy, Br J Surg, 2006;93:929–36.
79. Wente MN, Shrikhande SV, Müller MW, et al., Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis, Am J Surg, 2007;193:171–83.
80. D’Andrea AA, Costantino V, Sperti C, Pedrazzoli S, Human fibrin sealant in pancreatic surgery: it is useful in preventing fistulas? A prospective randomized study, Ital J Gastroenterol, 1994;26:283–6.
81. Tran K, Van Eijck C, Di Carlo V, et al., Occlusion of the pancreatic duct versus pancreaticojejunostomy: a prospective randomized trial, Ann Surg, 2002;236:422–8.
82. Suc B, Msika S, Fingerhut A, et al.; and the French Associations for Surgical Research, Temporary fibrin glue occlusion of the main pancreatic duct in the prevention of intra-abdominal complications after pancreatic resection: prospective randomized trial, Ann Surg, 2003;237:57–65. 83. Klempa I, Baca I, Menzel J, Schuszdiarra V, Effect of
somatostatin on basal and stimulated exocrine pancreatic secretion after partial duodenopancreatectomy. A clinical experimental study, Chirurg, 1991;62:293–9.
84. Büchler M, Friess H, Klempa I, et al., Role of octreotide in the prevention of postoperative complications following pancreatic resection, Am J Surg, 1992;163:125–30, discussion 130–1.
85. Bassi C, Falconi M, Lombardi D, et al., Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Italy. Italian Study Group, Digestion, 1994;55(Suppl. 1):41–7.
86. Pederzoli P, Bassi C, Falconi M, Camboni MG, Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group, Br J Surg, 1994;81:265–9.
87. Montorsi M, Zago M, Mosca F, et al., Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial, Surgery, 1995;117:26–31.
88. Friess H, Klempa I, Hermanek P, et al., Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Germany, Digestion, 1994;55(Suppl. 1): 35–40.
89. Friess H, Beger HG, Sulkowski U, et al., Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis, Br J Surg, 1995;82:1270–3. Erratum: Br J Surg, 1996;83:126.
90. Lowy AM, Lee JE, Pisters PW, et al., Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease, Ann Surg, 1997;226:632–41.
91. Yeo CJ, Cameron JL, Lillemoe KD, et al., Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial, Ann Surg, 2000;232:419–29.
92. Gouillat C, Chipponi J, Baulieux J, et al., Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy, Br J Surg, 2001;88:1456–62.
93. Shan YS, Sy ED, Lin PW, Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenectomy in high-risk patients and elimination of surgeon-related factors: prospective, randomized, controlled trial, World J Surg, 2003;27:709–14.
94. Sarr MG; Pancreatic Surgery Group, The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo- controlled trial, J Am Coll Surg, 2003;196:556–64.
95. Suc B, Msika S, Piccinini M, et al.; French Associations for Surgical Research, Octreotide in the prevention of intra- abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial, Arch Surg, 2004;139:288–94.
96. Hesse UJ, De Decker C, Houtmeyers P, et al., Prospectively randomized trial using perioperative low dose octreotide to prevent organ related and general complications following pancreatic surgery and pancreatico-jejunostomy, Acta Chir Belg, 2005;105:383–7.
97. Li-Ling J, Irving M, Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials, Br J Surg, 2001;88:190–9.
98. Connor S, Alexakis N, Garden OJ, et al., Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery, Br J Surg, 2005;29:1059–67.
99. Alghamdi AA, Jawas AM, Hart RS, Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis, Am J Surg, 2007;50:459–66.
100. Zeng Q, Zhang Q, Han S, et al., Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials, Pancreas, 2008;36:18–25.
101. Nordback IH, Hruban RH, Boitnott JK, et al., Carcinoma of the body and tail of the pancreas, Am J Surg, 1992;164:26–31.
102. Sperti C, Pasquali C, Pedrazzoli S, Ductal adenocarcinoma of the body and tail of the pancreas, J Am Coll Surg, 1997;185:255–9.
103. Lillemoe KD, Kaushal S, Cameron JL, et al., Distal pancreatectomy: indications and outcomes in 235 patients, Ann Surg, 1999;229:693–8, discussion 698–700.
104. Falconi M, Mantovani W, Bettini R, et al., Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade?, Dig Liver Dis, 2003;35:421–7.
105. Shoup M, Conlon KC, Klimstra D, Brennan MF, Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?, J Gastrointest Surg, 2003;7:946–52.
106. Bergenfeldt M, Moesgaard F, Burcharth F, Curative resection for left-sided pancreatic malignancy, HPB (Oxford), 2006;8:211–5.
107. Miyata M, Dousei T, Tanaka Y, et al., Surgical aspect of cancer of the distal pancreas. Comparison of operative findings, mortality, morbidity, physicalperformance status and survival in cancer of the proximal and distal pancreas, Dig Surg, 1991;8:225–30.
108. Fujimori N, Nakamura T, Oono T, et al., Adenocarcinoma involving the whole pancreas with multiple pancreatic masses, Intern Med, 2010;49:1527–32.
109. Pedrazzoli S, DiCarlo V, Dionigi R, et al., Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group, Ann Surg, 1998;228:508–17.
110. Yeo CJ, Cameron JL, Sohn TA, et al.,
Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome, Ann Surg, 1999;229:613–22.
111. Riall TS, Cameron JL, Lillemoe KD, et al., Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma – part 3: update on 5-year survival, J Gastrointest Surg, 2005;9:1191–1204.
112. Nguyen TC, Sohn TA, Cameron JL, et al., Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors, J Gastrointest Surg, 2003;7:1–9.
113. Farnell MB, Pearson RK, Sarr MG, et al.; Pancreas Cancer Working Group, A prospective randomized trial comparing standard pancreatoduodenectomy with
pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma, Surgery, 2005;138:618–28.
114. Iqbal N, Lovegrove RE, Tilney HS, et al., A comparison of pancreaticoduodenectomy with extended pancreaticoduodenectomy: a meta-analysis of 1909 patients, Eur J Surg Oncol, 2009;35:79–86.
115. Breslin TM, Hess KR, Harbison DB, et al., Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas : treatment variables and survival duration, Ann Surg Oncol, 2001;8:123–32.
116. Siriwardana HP, Siriwardena AK, Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer, Br J Surg, 2006;93:662–73.
117. Boggi U, Del Chiaro M, Croce C, et al., Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer, Surgery, 2009;146:869–81.
118. Allison DC, Piantadosi S, Hruban RH, et al., DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma, J Surg Oncol, 1998;67:151–9.
119. Moertel CG, Childs DS Jr, Reitemeier RJ, et al., Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer, Lancet, 1969;2:865–7.
120. Tepper J, Nardi G, Suit H, Carcinoma of the pancreas : Review of MGH experience from 1963 to 1973: Analysis of surgical failure and implication for radiation therapy, Cancer, 1976;37:1519–24.
121. Pilepich MV, Miller HH, Preoperative irradiation in carcinoma of the pancreas, Cancer, 1980;46:1945–9.
122. Moertel CG, Frytak S, Hahn RG, et al., Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group, Cancer, 1981;48:1705–10.
123. Kopelson G, Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre- or postoperative radiation therapy, Int J Radiat Oncol Biol Phys, 1983;9:911–5.
124. Kalser MH, Ellenberg SS, Pancreatic Cancer. Adjuvant combined radiation and chemotherapy following curative radiation, Arch Surg, 1985;120:899–903.
125. The Gastrointestinal Tumor Study Group (GITSG), Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer, Cancer, 1987;59:2006–10.
126. Whittington R, Bryer MP, Haller DG, et al., Adjuvant therapy of resected adenocarcinoma of the pancreas, Int J Radiat Oncol Biol Phys, 1991;21:1137–43.
127. Foo ML, Gunderson LL, Nagorney DM, et al., Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ± 5 fluorouracil, Int J Radiat Oncol Biol Phys, 1993;26:483–9.
128. Abrams RA, Grochow LB, Chakravarthy A, et al., Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma : survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels, Int J Radiat Oncol Biol Phys, 1999;44:1039–46.
129. Paulino AC, Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure, Am J Clin Oncol, 1999;22:489–94.
130. Mehta VK, Fisher GA, Ford JM, et al., Adjuvant radiotherapy and concomitant 5-Fluorouracil by protracted venous infusion for resected pancreatic cancer, Int J Radiat Oncol Biol Phys, 2000;48:1483–7.
131. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B, Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of
EUROPEAN ONCOLOGY & HAEMATOLOGY 41
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84
| Page 85
| Page 86
| Page 87
| Page 88
| Page 89
| Page 90
| Page 91
| Page 92